UPDATE: Needham & Company Upgrades Acadia Pharmaceuticals (ACAD) to Buy, $9 Price Target
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Acadia Pharma (ACAD) Met Primary Endpoint in Pimavanserin Phase III
November 27, 2012 7:27 AM ESTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) announced successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinsons disease psychosis (PDP). Pimavanserin is ACADIAs proprietary, non-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors. Pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinsons Disease Rating Scale,... More
Acadia Pharma (ACAD) Halted Ahead of Pivotal Pimavanser Phase III Presentation
November 27, 2012 7:25 AM ESTAcadia Pharmaceuticals, Inc. (NASDAQ: ACAD) shares are halted Tuesday morning ahead of the company's conference call and webcast to present the top-line results from its pivotal Phase III trial with pimavanserin in patients with Parkinsons disease psychosis (PDP).
The... More
Acadia Pharmaceuticals (ACAD) Jumps Ahead of Data Presentation
November 26, 2012 5:47 PM ESTShares of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) are up 6.5 percent after-hours Monday after the company announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, November 27, 2012 to present the top-line results from its pivotal Phase III trial with... More
